POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
POSTERS
Subgroup Analysis of Non-Squamous EGFR Wild-Type (WT) 2nd/3rdLine NSCLC Patients from the Global Phase 3 Trial DUBLIN-3 (BPI-2358-103) with the Plinabulin/Docetaxel Combination vs. Docetaxel Alone (2022)
10.2022
American Society of Clinical Oncology (ASCO) Annual Meeting (2022)
Subgroup Analysis of Non-Squamous EGFR Wild-Type (WT) 2nd/3rdLine NSCLC Patients from the Global Phase 3 Trial DUBLIN-3 (BPI-2358-103) with the Plinabulin/Docetaxel Combination vs. Docetaxel Alone
American Society of Hematology (ASH) Annual Meeting (2021)
12.2021
American Society of Hematology (ASH) Annual Meeting (2021)
PLINABULIN RAPIDLY (WITHIN 24 HOURS) REVERSES MYELOSUPPRESSION INDUCED BY CHEMOTHERAPY
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
12.2021
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
Combination Plinabulin+Pegfilgrastim (Plin+Peg) Had Better Toxicity Management and Health Related Quality-of-Life (HrQoL) Compared to Peg Alone in Early-stage Breast Cancer (BC) Patients (pts) Treated With Taxotere, Doxorubicin and Cyclophosphamide (TAC)
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
12.2021
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
Mechanistic evidence associated with the benefit of plinabulin significantly reducing bone pain in breast cancer patients (pts)
treated with TAC (Docetaxel, Doxorubicin, Cyclophosphamide) and Pegfilgrastim (Peg)
Subgroup Analysis of Non-Squamous EGFR Wild-Type (WT) 2nd/3rdLine NSCLC Patients from the Global Phase 3 Trial DUBLIN-3 (BPI-2358-103) with the Plinabulin/Docetaxel Combination vs. Docetaxel Alone (2022)
10.2022
American Society of Clinical Oncology (ASCO) Annual Meeting (2022)
Subgroup Analysis of Non-Squamous EGFR Wild-Type (WT) 2nd/3rdLine NSCLC Patients from the Global Phase 3 Trial DUBLIN-3 (BPI-2358-103) with the Plinabulin/Docetaxel Combination vs. Docetaxel Alone
American Society of Hematology (ASH) Annual Meeting (2021)
12.2021
American Society of Hematology (ASH) Annual Meeting (2021)
PLINABULIN RAPIDLY (WITHIN 24 HOURS) REVERSES MYELOSUPPRESSION INDUCED BY CHEMOTHERAPY
PUBLICATIONS
JNCCN 2023
09.2023
JNCCN
Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy
JAMA Network Open 2022
01.27.2022
JAMA
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced
Neutropenia in Patients With Solid Tumors
JAMA Oncology 2020
09.24.2020
JAMA Oncology
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced
Neutropenia in Patients With Solid Tumors
Cancer Chemotherapy and Pharmacology
12.06.2019
Cancer Chemotherapy and Pharmacology
Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies
JNCCN 2023
09.2023
JNCCN
Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy
JAMA Network Open 2022
01.27.2022
JAMA
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced
Neutropenia in Patients With Solid Tumors